Novel Dual‐acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients Results of 24 Week Treatment in a Phase III Monotherapy Trial (SEED Study)
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
沪公网安备 31011502013809号 Privacy Statement Terms of Use
